BioSpace News Archive

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) is pleased to announce a non-brokered private placement of units (“Units”) at a price of $0.25 per Unit for gross proceeds of $2,000,000 (the “Offering”).

Reflow Medical, Inc. announced that it has received FDA commercial clearance for its coraCatheters™, a complete line of state-of-the-art microcatheters engineered to access and cross complex and challenging lesions in percutaneous coronary interventions.

Tempest Therapeutics, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 12,600 shares of its common stock with an exercise price equal to the closing price of Tempest’s common stock on May 15, 2023, the grant date of the award.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced that it expects to release topline results from the Phase 2 ALTITUDE-NASH clinical trial before the market opens on Monday, May 22, 2023.

Calyxt, Inc. announced the results of the special meeting of its stockholders held on May 18, 2023.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that two members of the Board of Directors have stepped down due to obligations associated with recent executive opportunities: Katrin Rupalla, PhD and Daniel O’Connor.

Forte Biosciences, Inc., a biopharmaceutical company focused on autoimmune diseases, announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.

Jaguar Health, Inc. announced that the Company’s New Employee Inducement Award Plan, which was adopted by Jaguar’s Board of Directors effective June 16, 2020, has been replenished with 499,171 shares of the Company’s common stock, par value $0.0001 per share.